Biogen's $5.6B Rare Disease Play & McCormick's $20B Flavor Empire

Biogen is making a massive $5.6 billion splash in the immunology and rare disease space by acquiring Apellis Pharmaceuticals. The definitive all-cash agreement, priced at $41.00 per share, is designed to bolster Biogen's growth portfolio and accelerate its expansion into nephrology. Also: McCormick & Company is combining with Unilever's Foods business to create a global flavor powerhouse with projected combined annual revenues of $20 billion.; Private equity giant Carlyle is acquiring a majority stake in MAI Capital Management, valuing the firm at over $2.8 billion.; Primoris Services Corporation is expanding its data center market exposure with a $422 million all-cash acquisition of PayneCrest Electric.

---

Subscribe for daily M&A insights and deal analysis.

Sign up free: https://ololand.ai/signup?ref=youtube

Free tools:
CIM Analyzer: https://ololand.ai/tools/cim-analyzer
Valuation Calculator: https://ololand.ai/tools/valuation-calculator
Academic Paper Publisher: https://ololand.ai/tools/academic-paper-publisher

#MergersAndAcquisitions #PrivateEquity #DueDiligence #DealStreetDaily #AI #SearchFunds

Видео Biogen's $5.6B Rare Disease Play & McCormick's $20B Flavor Empire канала ololandai